secwatch.observer — SEC 8-K summary
======================================

Issuer:     ACURA PHARMACEUTICALS, INC (—)
CIK:        0000786947
Form:       8-K
Filed at:   2025-12-29T23:59:59+00:00
Accession:  0001104659-25-124500
Event type: debt
Sentiment:  negative
Materiality: 0.90
Item codes: 1.01, 2.01, 2.03, 9.01
LLM model:  deepseek-v4-flash:cloud

Acura Pharmaceuticals extends debt maturity, secures additional loans from AD Pharma, warns of possible shutdown
--------------------------------------------------------------------------------

- Received $300k in three new loans from Abuse Deterrent Pharma, raising principal to $9,294,279 at 5.25% interest.
- Amended license agreement for LTX-03, extending FDA NDA acceptance deadline from Dec 31, 2025 to June 30, 2026.
- Extended maturity of secured promissory note and warrant expiration to June 30, 2026.
- AD Pharma now directly owns approximately 65% of Acura's outstanding common stock.
- Company warns it may scale back operations or seek bankruptcy protection if additional financing is not obtained by end of December 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/786947/000110465925124500/0001104659-25-124500-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/786947/000110465925124500/tm2534375d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-124500

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer